Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Response to comment on Goldfine et al. Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD). Diabetes care 2013;36:4132-4139.

Goldfine AB, Jablonski KA, Shoelson SE, Creager MA; TINSAL-FMD (Targeting Inflammation Using Salsalate in Type 2 Diabetes–Flow-Mediated Dilation) Ancillary Study Team.

Diabetes Care. 2014 May;37(5):e112. doi: 10.2337/dc14-0222. No abstract available.

2.
3.

Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD).

Goldfine AB, Buck JS, Desouza C, Fonseca V, Chen YD, Shoelson SE, Jablonski KA, Creager MA; TINSAL-FMD (Targeting Inflammation Using Salsalate in Type 2 Diabetes–Flow-Mediated Dilation) Ancillary Study Team.

Diabetes Care. 2013 Dec;36(12):4132-9. doi: 10.2337/dc13-0859. Epub 2013 Oct 15.

4.

Effect of estrogen on endothelial dysfunction in postmenopausal women with diabetes.

Lee SJ, Lee DW, Kim KS, Lee IK.

Diabetes Res Clin Pract. 2001 Dec;54 Suppl 2:S81-92.

PMID:
11733113
5.

Potential role of salicylates in type 2 diabetes.

Rumore MM, Kim KS.

Ann Pharmacother. 2010 Jul-Aug;44(7-8):1207-21. doi: 10.1345/aph.1M483. Epub 2010 Jun 1. Review.

PMID:
20516365
6.

Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes.

Goldfine AB, Silver R, Aldhahi W, Cai D, Tatro E, Lee J, Shoelson SE.

Clin Transl Sci. 2008 May;1(1):36-43. doi: 10.1111/j.1752-8062.2008.00026.x.

7.

The effect of salsalate therapy on endothelial function in a broad range of subjects.

Nohria A, Kinlay S, Buck JS, Redline W, Copeland-Halperin R, Kim S, Beckman JA.

J Am Heart Assoc. 2014 Jan 3;3(1):e000609. doi: 10.1161/JAHA.113.000609.

8.

Summaries for patients. The effects of salsalate on blood sugar control in people with type 2 diabetes.

[No authors listed]

Ann Intern Med. 2010 Mar 16;152(6):I-40. doi: 10.7326/0003-4819-152-6-201003160-00001. No abstract available.

PMID:
20231550
9.

Determinants of vascular function in patients with type 2 diabetes.

Naka KK, Papathanassiou K, Bechlioulis A, Kazakos N, Pappas K, Tigas S, Makriyiannis D, Tsatsoulis A, Michalis LK.

Cardiovasc Diabetol. 2012 Oct 12;11:127. doi: 10.1186/1475-2840-11-127.

10.

The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.

Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE; TINSAL-T2D (Targeting Inflammation Using Salsalate in Type 2 Diabetes) Study Team.

Ann Intern Med. 2010 Mar 16;152(6):346-57. doi: 10.7326/0003-4819-152-6-201003160-00004.

11.

Effect of paricalcitol on endothelial function and inflammation in type 2 diabetes and chronic kidney disease.

Thethi TK, Bajwa MA, Ghanim H, Jo C, Weir M, Goldfine AB, Umpierrez G, Desouza C, Dandona P, Fang-Hollingsworth Y, Raghavan V, Fonseca VA.

J Diabetes Complications. 2015 Apr;29(3):433-7. doi: 10.1016/j.jdiacomp.2015.01.004. Epub 2015 Jan 13.

12.

Salsalate improves glycemic control in patients with newly diagnosed type 2 diabetes.

Faghihimani E, Aminorroaya A, Rezvanian H, Adibi P, Ismail-Beigi F, Amini M.

Acta Diabetol. 2013 Aug;50(4):537-43. doi: 10.1007/s00592-011-0329-2. Epub 2011 Sep 22.

PMID:
21938543
13.

Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans.

Pierce GL, Lesniewski LA, Lawson BR, Beske SD, Seals DR.

Circulation. 2009 Mar 10;119(9):1284-92. doi: 10.1161/CIRCULATIONAHA.108.804294. Epub 2009 Feb 23.

14.

Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial.

Goldfine AB, Fonseca V, Jablonski KA, Chen YD, Tipton L, Staten MA, Shoelson SE; Targeting Inflammation Using Salsalate in Type 2 Diabetes Study Team.

Ann Intern Med. 2013 Jul 2;159(1):1-12. doi: 10.7326/0003-4819-159-1-201307020-00003.

15.

Folic acid improves endothelial dysfunction in type 2 diabetes--an effect independent of homocysteine-lowering.

Title LM, Ur E, Giddens K, McQueen MJ, Nassar BA.

Vasc Med. 2006 May;11(2):101-9.

PMID:
16886840
16.

Endothelial-dependent vasodilation and incidence of type 2 diabetes in a population of healthy postmenopausal women.

Rossi R, Cioni E, Nuzzo A, Origliani G, Modena MG.

Diabetes Care. 2005 Mar;28(3):702-7.

PMID:
15735211
17.

Rosiglitazone improves endothelial function in patients with type 2 diabetes treated with insulin.

Naka KK, Papathanassiou K, Bechlioulis A, Pappas K, Kazakos N, Kanioglou C, Papafaklis MI, Kostoula A, Vezyraki P, Makriyiannis D, Tsatsoulis A, Michalis LK.

Diab Vasc Dis Res. 2011 Jul;8(3):195-201. doi: 10.1177/1479164111408628. Epub 2011 May 16.

PMID:
21576196
18.

Metabolic syndrome individuals with and without type 2 diabetes mellitus present generalized vascular dysfunction: cross-sectional study.

Walther G, Obert P, Dutheil F, Chapier R, Lesourd B, Naughton G, Courteix D, Vinet A.

Arterioscler Thromb Vasc Biol. 2015 Apr;35(4):1022-9. doi: 10.1161/ATVBAHA.114.304591. Epub 2015 Feb 5.

19.

Insulin and non-insulin mediated vasodilation and glucose uptake in patients with type 2 diabetes.

Scheede-Bergdahl C, Olsen DB, Reving D, Boushel R, Dela F.

Diabetes Res Clin Pract. 2009 Sep;85(3):243-51. doi: 10.1016/j.diabres.2009.06.029. Epub 2009 Jul 28.

PMID:
19640601
20.

Supplemental Content

Support Center